JP2021527051A5 - - Google Patents

Info

Publication number
JP2021527051A5
JP2021527051A5 JP2020567845A JP2020567845A JP2021527051A5 JP 2021527051 A5 JP2021527051 A5 JP 2021527051A5 JP 2020567845 A JP2020567845 A JP 2020567845A JP 2020567845 A JP2020567845 A JP 2020567845A JP 2021527051 A5 JP2021527051 A5 JP 2021527051A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
och
nhc
nhch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020567845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527051A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035462 external-priority patent/WO2019236631A1/en
Publication of JP2021527051A publication Critical patent/JP2021527051A/ja
Publication of JP2021527051A5 publication Critical patent/JP2021527051A5/ja
Pending legal-status Critical Current

Links

JP2020567845A 2018-06-05 2019-06-04 ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用 Pending JP2021527051A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862680891P 2018-06-05 2018-06-05
US62/680,891 2018-06-05
US201962831006P 2019-04-08 2019-04-08
US62/831,006 2019-04-08
PCT/US2019/035462 WO2019236631A1 (en) 2018-06-05 2019-06-04 Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses

Publications (2)

Publication Number Publication Date
JP2021527051A JP2021527051A (ja) 2021-10-11
JP2021527051A5 true JP2021527051A5 (https=) 2022-06-27

Family

ID=67185700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567845A Pending JP2021527051A (ja) 2018-06-05 2019-06-04 ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用

Country Status (5)

Country Link
US (1) US11046699B2 (https=)
EP (1) EP3802544A1 (https=)
JP (1) JP2021527051A (https=)
TW (1) TW202016112A (https=)
WO (1) WO2019236631A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499644B (zh) * 2020-04-24 2021-07-20 苏州大学 咪唑并[1,5-a]喹唑啉-5(4H)-酮类衍生物及其制备方法和用途
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
CN114516828A (zh) * 2020-11-19 2022-05-20 江苏威奇达药业有限公司 一种提高负氮杂提取率的提取工艺
US20250000859A1 (en) * 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors
KR20240157639A (ko) 2021-12-14 2024-11-01 크로스파이어 온콜로지 홀딩 비.브이. 거대고리 btk 억제제
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2024126617A1 (en) 2022-12-14 2024-06-20 Crossfire Oncology Holding B.V. Bifunctional compounds for degrading kinases via ubiquitin proteosome pathway
WO2024238570A1 (en) * 2023-05-15 2024-11-21 Aleksia Therapeutics, Inc. Cdk2 inhibitor pyrazolopyrimidine compounds
CN117756677B (zh) * 2023-12-21 2025-09-30 上海馨远医药科技有限公司 一种手性反式-n-boc-1-氨基环戊烷-3-甲酸的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
WO2003029209A2 (en) * 2001-10-02 2003-04-10 Smithkline Beecham Corporation Chemical compounds
CA2676665A1 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Modulators of mitotic kinases
US20130345268A1 (en) 2009-02-13 2013-12-26 The Trustees Of Dartmouth College Methods and Compositions for the Treatment of RAS Associated Disorders
US8362023B2 (en) * 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
AU2014224975B2 (en) * 2013-03-05 2017-09-14 Merck Patent Gmbh Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents

Similar Documents

Publication Publication Date Title
JP2021527051A5 (https=)
JP2007501859A5 (https=)
JP2018519357A5 (https=)
JP2016526558A5 (https=)
RU2403258C2 (ru) Тиазолилдигидроиндазолы
JP2021514001A5 (https=)
JP2020169171A5 (https=)
RU2007109870A (ru) 2,4-ди(аминофенил)пиримидины в качестве ингибиторов plk-киназ
RU2001132635A (ru) Производные пиперидина, применимые в качестве антагонистов сс R5
HRP20250099T1 (hr) Agonisti receptora glp-1 i njihova upotreba
JP2020500182A5 (https=)
RU2010111551A (ru) Замещенные индольные производные и способы их применения
RU2001132632A (ru) Производные пиперазина, применимые в качестве антагонистов CCR5
JP2004516314A5 (https=)
RU2003133448A (ru) 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс- хемокинового рецептора
JP2009536660A5 (https=)
JP2017506250A5 (https=)
RU2018118216A (ru) Соединения пуринона в качестве ингибиторов киназ
HRP20160046T1 (hr) Poboljšana citotoksiäśna sredstva koja sadrže nove majtanzinoide
JP2012510523A5 (https=)
AR120652A1 (es) Antagonistas de sstr5
JP2008505117A5 (https=)
RU2010103160A (ru) ПРОИЗВОДНЫЕ 2-[(2-{ФЕНИЛАМИНО}-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА
AR032569A1 (es) Ligandos del receptor de canabinoide
JP2021530559A5 (https=)